https://orcid.org/0000-0002-4151-3916
References
- Adams D , Gonzalez-DuarteA , O'riordanWDet al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med.379(1), 11–21 (2018).
- Ruigrok MJR , FrijlinkHW , HinrichsWLJ. Pulmonary administration of small interfering RNA: the route to go?J. Control. Rel.235, 14–23 (2016).
- Thanki K , BlumKG , ThakurA , RoseF , FogedC. Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities. Ther. Deliv.9(10), 731–749 (2018).
- Aigner A , KögelD. Nanoparticle/siRNA-based therapy strategies in glioma: which nanoparticles, which siRNAs?Nanomedicine (Lond.)13(1), 89–103 (2018).
- Weber S , ZimmerA , PardeikeJ. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur. J. Pharm. Biopharm.86(1), 7–22 (2014).
- Levy ML , HardwellA , McknightE , HolmesJ. Asthma patients' inability to use a pressurised metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the global initiative for asthma (GINA) strategy: a retrospective analysis. Prim. Care Respir. J.22(4), 406 (2013).
- Saleem I , DiezF , JonesB , KayaliN , PoloL. Investigation on the aerosol performance of dry powder inhalation hypromellose capsules with different lubricant levels. Int. J. Pharm.492(1–2), 258–263 (2015).
- Demoly P , HagedoornP , DeBoer AH , FrijlinkHW. The clinical relevance of dry powder inhaler performance for drug delivery. Respir. Med.108(8), 1195–1203 (2014).
- Patil J , SarasijaS. Pulmonary drug delivery strategies: a concise, systematic review. Lung India29(1), 44 (2012).
- Yang MY , ChanJGY , ChanH-K. Pulmonary drug delivery by powder aerosols. J. Control. Rel.193, 228–240 (2014).
- Barham AS , TewesF , HealyAM. Moisture diffusion and permeability characteristics of hydroxypropylmethylcellulose and hard gelatin capsules. Int. J. Pharm.478(2), 796–803 (2015).
- Liang W , ChanAY , ChowMYet al. Spray freeze drying of small nucleic acids as inhaled powder for pulmonary delivery. Asian J. Pharm.13(2), 163–172 (2018).
- Leng D , ThankiK , FogedC , YangM. Formulating inhalable dry powders using two-fluid and three-fluid nozzle spray drying. Pharm. Res.35(12), 247 (2018).
- Liang W , ChowMY , ChowSF , ChanH-K , KwokPC , LamJK. Using two-fluid nozzle for spray freeze drying to produce porous powder formulation of naked siRNA for inhalation. Int. J. Pharm.552(1–2), 67–75 (2018).
- Okuda T , MorishitaM , MizutaniK , ShibayamaA , OkazakiM , OkamotoH. Development of spray-freeze-dried siRNA/PEI powder for inhalation with high aerosol performance and strong pulmonary gene silencing activity. J. Control. Rel.279, 99–113 (2018).
- Merkel OM , RubinsteinI , KisselT. siRNA delivery to the lung: what's new?Adv. Drug Deliv. Rev.75, 112–128 (2014).
- Hoppentocht M , HagedoornP , FrijlinkH , DeBoer A. Technological and practical challenges of dry powder inhalers and formulations. Adv. Drug Deliv. Rev.75, 18–31 (2014).
- Ziaee A , AlbadarinAB , PadrelaL , FemmerT , O'reillyE , WalkerG. Spray drying of pharmaceuticals and biopharmaceuticals: critical parameters and experimental process optimization approaches. Eur. J. Pharm. Sci.127, 300–318 (2018).
- Vehring R . Pharmaceutical particle engineering via spray drying. Pharm. Res.25(5), 999–1022 (2008).
- Chow MYT , QiuY , LoFFKet al. Inhaled powder formulation of naked siRNA using spray drying technology with L-leucine as dispersion enhancer. Int. J. Pharm.530(1-2), 40–52 (2017).